Expert guidance on fecal microbiota transplantation in liver disease
The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT),…
Preclinical study reveals potential new treatment for severe liver fibrosis
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis – a dangerous, disease-induced build-up of…
Frequency and quantity of alcohol consumption influence cancer risk
As Americans gear up for the holiday season, new research offers a timely reminder to reflect on the…
Sugar alcohol sorbitol may increase the risk of developing steatotic liver disease
Sweeteners such as aspartame, found in Equal packets, sucralose (Splenda), or sugar alcohols are often seen as healthier…
Understanding thrombocytopenia in patients with portal hypertension and chronic liver disease
Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal hypertension…
GLP-1 goliath updates demand for top weight loss drug
Novo Nordisk reported Q3 2025 earnings on November 5, showing continued strong demand for its weight-loss drug Wegovy,…
E2F2 protein identified as potential therapeutic target to prevent metabolic fatty liver disease progression
An international collaborative study has identified the E2F2 protein as a potential new therapeutic target to prevent metabolic…
Scientists question the safety and efficacy of the diet for metabolic health
A study published in Science Advances by University of Utah Health researchers sheds light on the long-term effects…
Nanoparticles offer new hope for treating alcohol-related liver disease
Across the world, more than 1.5 billion people suffer from chronic liver disease. The U.S. Centers for Disease…
Study links gut dysbiosis with severe steatosis in MASLD
A new study in eGastroenterology links gut dysbiosis with severe steatosis in metabolic dysfunction–associated steatotic liver disease (MASLD). In a…
Japan’s registry transforms outcomes for infants with biliary atresia
Biliary atresia (BA) is the leading cause of liver failure in infants, marked by progressive destruction of the…
Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third…